Low-Risk TAVR Converging or Diverging With Surgical Outcomes, Depending on the Valve
(MedPage Today) -- SAN FRANCISCO -- A handful of years later, transcatheter aortic valve replacement (TAVR) still compared well against surgery in the PARTNER 3 and Evolut Low Risk trials.
PARTNER 3 appeared to show a convergence of the TAVR...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Heart | Heart Valve Surgery